FYERS
Dr Lalchandani Labs8.22
+0.00 (+0.00%)

Dr Lalchandani Labs Share Price

8.22+0.00 (+0.00%)
-51.67% past 1 Year

Corporate filings & documents

Announcements

The company due to ill health of the Chairman of the Company had filed the Application for extension of Annual General Meeting (AGM) for FY 2025-26 the ROC Delhi has considered and approved the application and granted the extension for the period of 3 month i.e. December 31 2026. Therefore the Company will hold the AGM for FY 2025-26 at the earliest but not later than December 31 2026.
4 days ago
The company due to ill health of the Chairman of the Company had filed the Application for extension of Annual General Meeting (AGM) for FY 2025-26 the ROC Delhi has considered and approved the application and granted the extension for the period of 3 month i.e. December 31 2026. Therefore the Company will hold the AGM for FY 2025-26 at the earliest but not later than December 31 2026.
4 days ago
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations for quarter ended June 2026
2 months ago
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations for quarter ended June 2026
2 months ago
Audited Financial Results for the quarter and year ended March 31 2026
3 months ago
Audited Financial Results for the quarter and year ended March 31 2026
3 months ago
Audited Financial Results for the half year and year ended March 31 2206
3 months ago
Audited Financial Results for the half year and year ended March 31 2206
3 months ago
Intimation of Postponement and Rescheduling of Board Meeting scheduled to be held on Today May 30 2026.
3 months ago
We are pleased to inform that the Company has successfully opened a new strategic Centre at Dwarka New Delhi.
3 months ago
Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve financial results of the Company for Half year and Year ended March 31 2026
3 months ago
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Dr Lalchandani Labs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85320DL2017PLC321605</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NA</td></tr><tr><td>Designation :-</td><td>NA</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Anchal Gupta</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 04/05/2026<br/><br/></div>
4 months ago
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Dr Lalchandani Labs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85320DL2017PLC321605</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NA</td></tr><tr><td>Designation :-</td><td>NA</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Anchal Gupta</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 04/05/2026<br/><br/></div>
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Dr Lalchandani Labs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85320DL2017PLC321605</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NA <br/> Designation: NA <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Anchal Gupta <br/> Designation: Chief FInancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Dr Lalchandani Labs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85320DL2017PLC321605</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NA <br/> Designation: NA <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Anchal Gupta <br/> Designation: Chief FInancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago
Resignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer
5 months ago
Resignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer
5 months ago
Reply to the clarification sought by exchange dated April 13 2026
5 months ago
Reply to the clarification sought by exchange dated April 13 2026
5 months ago
The Exchange has sought clarification from Dr Lalchandani Labs Ltd on April 13 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
5 months ago
Certificate under Regulation 74(5) of SEBI DP Regulations for Quarter ended March 2026
5 months ago
Certificate under Regulation 74(5) of SEBI DP Regulations for Quarter ended March 2026
5 months ago
Trading Window Closure for March 31 2026
5 months ago
Trading Window Closure for March 31 2026
5 months ago
post issue newspaper advertisements under Regulation 92
6 months ago
post issue newspaper advertisements under Regulation 92
6 months ago
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Anuraag Gambhir
6 months ago
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Anuraag Gambhir
6 months ago
Approval of basis of allotment under Right issue
6 months ago
Board meeting for approval of basis of allotment for right issue
6 months ago
Newspaper publication for extension of issue closing date and extension of date of on market renunciation of Rights Entitlements.
7 months ago
Newspaper publication for extension of issue closing date and extension of date of on market renunciation of Rights Entitlements.
7 months ago
We wish to inform you that the Board of Directors of the Company considered and approved the extension of closing date of the ongoing right issue. The issue has been extended to February 27 2026 from the earlier issue closing date February 20 2026
7 months ago
We wish to inform you that the Board of Directors of the Company considered and approved the extension of closing date of the ongoing right issue. The issue has been extended to February 27 2026 from the earlier issue closing date February 20 2026
7 months ago
This is in reference to the Outcome of the Meeting of Board of Directors dated January 20 2026 we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited at its meeting held on today i.e. February 16 2026 has considered and approved the extension of the closing date of the ongoing rights issue.The Rights Issue which opened on Wednesday February 04 2026 and originally scheduled to close on Friday February 20 2026 has now been extended until Friday February 27 2026. The extension has been granted to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the Rights Issue.
7 months ago
This is in reference to the Outcome of the Meeting of Board of Directors dated January 20 2026 we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited at its meeting held on today i.e. February 16 2026 has considered and approved the extension of the closing date of the ongoing rights issue.The Rights Issue which opened on Wednesday February 04 2026 and originally scheduled to close on Friday February 20 2026 has now been extended until Friday February 27 2026. The extension has been granted to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the Rights Issue.
7 months ago
Corrigendum to the newspaper publication dated January 31 2026
7 months ago
Newspaper publication as per stated regulation
7 months ago
Please find enclosed the soft copy of Letter of Offer dated January 20 2026 for the Rights Issue of Dr Lalchandani Labs Limited. The Company is also submitting this Letter of Offer with Securities and Exchange Board of India (SEBI) for its information in compliance with SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and SEBI Circular bearing no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11 2025.
8 months ago
ntimation of Record Date pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations)
8 months ago
In continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
8 months ago
In continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
8 months ago
In continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
8 months ago
We are pleased to inform that the company has received the In-principle approval from BSE Limited for Rights issue of Equity Shares the letter is enclosed
8 months ago
Compliance Certificate under Regulation 74(5) for Quarter ended December 31 2025
8 months ago
This is with reference to our prior intimation dated December 16 2025 wherein we had informed the Exchange about the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) scheduled to be held on Monday December 22 2025 inter alia to consider and approve matters relating to the proposed Rights Issue including fixation of the record date issue price entitlement ratio and other related terms.We wish to inform you that the aforesaid Board Meeting scheduled to be held on December 22 2025 has been deferred due to the non-receipt of In-Principle Approval from BSE Limited for the proposed Rights Issue.
9 months ago
Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/12/2025 inter alia to consider and approve fixation of the record date;? determination of the issue price;? determination of the rights entitlement ratio; and? such other terms and conditions as may be required in accordance with applicable laws subject to receipt of necessary statutory and regulatory approvals.
9 months ago
Board of Directors in the Board Meeting held today has approved the raising of fund by way of right issue to the eligible equity shareholders as on record date (to be determined and specified subsequently)
9 months ago
Raising of funds through the issuance of equity shares of face value ?10 each by way of rights issue for an amount not exceeding Rs 433.31 Lakhs to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently) subject to receipt of statutory / regulatory approvals in accordance with the amended SEBI (Issuer of Capital and Disclosure Requirements) Amendment Regulations 2025 (the "SEBI ICDR Regulations") and other applicable regulations and subject to necessary approvals as may be required.
9 months ago
Outcome of Board Meeting
9 months ago

Annual reports

FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

Empty box

No presentations found

Dr Lalchandani Labs Ltd Share Price Today

The Dr Lalchandani Labs Ltd share price today is ₹7.64. During the trading session, the Dr Lalchandani Labs Ltd share price opened at ₹0.00 and recorded an intraday high of ₹0.00 and a low of ₹0.00. Last closing price was ₹7.64. Over the past 52 weeks, the Dr Lalchandani Labs Ltd share price has ranged between ₹5.97 and ₹19.21. The current Dr Lalchandani Labs Ltd stock price reflects real-time market activity based on executed trades on the exchange.